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1. Introduction
   The glucose-6-phosphate dehydrogenase (G6PD) deficiency 
is the most common disease-producing enzymopathy in 
humans, affecting 400 million people worldwide[1,2]. Its 
prevalence is highest in malaria endemic areas, because of the 
selective advantage conferred to carriers against malaria[3,4]. 
Approximately 140 mutations or combinations of mutations 
responsible for this deficiency have been described[5-7]. 
In sub-Saharan Africa, 3 variants occur with polymorphic 
frequencies above 1%: wild type G6PD B, a non-deficient 
variant G6PD A and the deficient variant G6PD A-[8,9]. The 
variant G6PD A results from a point mutation A376G in exon 5 
whereas the deficient variant G6PD A- has an A376G mutation 
and an additional one G202A in exon 4. Other deficient variants 
associate the mutation A376G and the following mutations: 
A542T (exon 6), G680T (exon 7) and T968C (exon 9) in the G6PD 
gene. 
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   In previous studies carried out in Burkina Faso, the G6PD 
deficiency has been explored mainly by measuring the 
enzymatic activities[10]. Furthermore, the genotyping of the 
G6PD variants have been focused on single 202A/376G G6PD 
A- variant considered as the most common in Africa[9,11]. 
However, studies in West Africa have shown the presence of 
point mutations other than 202A/376G associated with the G6PD 
deficiency with relatively high frequencies. In fact, it has been 
shown that the 376G/542T G6PD Santamaria, 376G/968C G6PD 
Betica Selma and T968C alleles were more frequent in Serer[11] 
and the general population in the Gambia[12]. In this study four 
combinations of mutations responsible for the G6PD deficiency 
were investigated in a rural community in Burkina Faso.
2. Materials and methods
2.1. Settings and type of study
   Unrelated participants were recruited in Koubri (a rural 
community located at 25 km south of Ouagadougou, Burkina 
Faso), where malaria transmission is perennial because of dams 
associated with agricultural activities. 
2.2. Study population 
   Two hundred individuals aged from 1 to 79 years were 
included. The participants were in their great majority from 
the Mossi ethnic group. They were already involved in another 
project entitled “Study of fine specific immune responses 
against Plasmodium falciparum (P. falciparum) peptides 
candidate vaccines”.
2.3. Blood collection
   Venous blood (5 mL of blood per adult and about 3 mL of 
blood per child) was collected on ethylene diamine tetraacetic 
acid impregnated tubes. After centrifugation at 15 000 r/min for 
5 min, plasma was separated from cell pellet. The pellet was 
stored at -20 °C for DNA extraction.
2.4. DNA extraction and genotyping of G6PD-deficient variants 
   All DNA samples were extracted using a standard salting-
out procedure[13] or the QIAamp DNA Mini Kit from QIAGEN 
(QIAGEN, Hilden, Germany). DNA purities were estimated 
spectrophotometrically, and the final concentrations were 
determined using Biodrop µLITE (Isogen Life Science N.V./S.A, 
Temse, Belgium). 
   The mutations A376G, G202A and A542T were genotyped with 
20 ng of DNA by the TaqMan assays (ABI, Applera International 
Inc, Foster City, CA, USA) in a reaction volume of 25 µL, using 
the ABI 7500 FAST real-time polymerase chain reaction (PCR) 
systems. Fluorescence curves were analyzed with the 7500 FAST 
Sequence Detection Software version v.2.1 (Applied Biosystems) 
for allelic discrimination. The G680T and T968C mutations 
were genotyped by PCR followed by restriction fragment length 
polymorphism (RFLP) (PCR/RFLP) as previously described by 
Beutler et al[14]. 
2.5. Statistical analysis
   Data were analyzed using the Statistical Package for Social 
Sciences 17.0 and EpiInfo version 6 software. The chi square 
test was used for comparisons. The difference was considered 
significant for P<0.05.
2.6. Ethical considerations
   This study was approved by the Ministry of Health and the 
CERBA/Saint Camille Ethics Committee. Informed consent was 
obtained from adults and parents or guardians of children under 
5 years before blood collection. 
3. Results
3.1. Prevalence of G6PD deficiency
   The study population consisted of 58% and 42% of women and 
men, respectively. Nearly three quarters of the subjects (74.5%) 
were carriers of the G6PD normal alleles; G6PD-heterozygous 
women represented 16.0% (32/200), while 9.5% (19/200) were 
202A/376G G6PD A-. None of the G6PD-deficient variants 
376G/542T, 376G/680T and 376G/968C were detected in this study 
(Table 1). The G6PD deficiency prevalence was significantly 
higher in men compared to women (14.3% vs 6.0%, P=0.049). 
Table 1
Prevalence of four combinations of mutations responsible for G6PD 
deficiency.
G6PD genotypes Number  Percentage 
Male 84 -
202A/376G hemizygous 12 14.3
376G/542T 0  0.0
376G/680T 0  0.0
376G/968C 0  0.0
G6PD normal 72 85.7
Female 116 -
202A/376G homozygous 7  6.0
202A/376G heterozygous 32 27.6
376G/542T 0  0.0
376G/680T 0  0.0
376G/968C 0  0.0
G6PD normal 77 66.4
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3.2. Asymptomatic malaria and G6PD
   The presence of the P. falciparum parasite was investigated 
in 15 out of the 19 G6PD-deficient individuals. The absence 
of parasitaemia was observed in 53.3% of the G6PD-deficient 
and 57.0% of the non-deficient persons, respectively. Among 
the G6PD-heterozygous women, P. falciparum asymptomatic 
malaria was found in 48.1% (13/27) of them. 
   No statistically significant difference was found by comparing 
the prevalence of P. falciparum infection between deficient and 
non-deficient persons on one hand, and between non-deficient 
and heterozygous individuals on the other hand. However, the 
geometric mean of parasites in infected individuals from the 3 
groups were significantly higher in the non-deficient compared 
to the deficient persons (1104 vs 204 parasites/µL, P<0.001) and 
also in the non-deficient compared with the individuals who 
are heterozygous (1104 vs 628 parasites/µL, P<0.001).
4. Discussion 
   In this study, we investigated four combinations of mutations 
(202A/376G; 376G/542T; 376G/680T; 376G/968T) responsible for 
G6PD deficiency in individuals living in a malaria endemic 
area, such as Burkina Faso. The G6PD deficiency prevalence 
was 9.5% in our study population. This prevalence is 
comparable to that of 9.0% reported by Carter et al[8], in six 
African countries, but lower than the prevalence of 19.6% and 
16.3% respectively reported by Modiano et al[15], and Simpore et 
al[10], in Burkina Faso. These variations could be explained not 
only by the small size of our population sample, but also by the 
diagnostic methods used for the detection of the G6PD (real-
time PCR, PCR/RFLP versus measurement of enzyme activity) 
deficiency. Furthermore, these differences could also be due to 
the difficulty of distinguishing deficient and non-deficient by 
genotyping heterozygous women[16]. 
   Indeed, in a previous study it was shown that among 81 G6PD 
heterozygous women, 53% had a normal enzyme activity, while 
33% had an intermediate activity and 14% had a biochemical 
deficiency[17].
   Four deficient genotypes were sought in this study, and only 
the genotype 202A/376G G6PD A- was found. These results 
are similar to those obtained by Carter et al[8], in six African 
countries including Burkina Faso, and confirms the results 
shown by previous studies that the 202A/376G G6PD A- is the 
most common deficient variant in sub-Saharan Africa[9,18]. 
The prevalence of G6PD deficiency was significantly higher 
among men (14.3%) compared to women (6.0%). These results 
are comparable to that found by Simpore et al. who observed 
20.5% of deficiency among men and 12.3% among women[10]. 
The prevalence of parasitaemia in infected individuals was 
significantly higher among those who are not deficient with 
respect to those who are deficient (P<0.001). In addition, 
heterozygous females had a significantly high prevalence of 
parasitaemia (P<0.001). 
   Our results are comparable to those of a study in Gabon 
which has shown that there is an association between the G6PD 
deficiency and the protection against asymptomatic malaria[19]. 
Indeed, G6PD deficiency seems to prevent the normal 
development of P. falciparum in the body. 
   The protection mechanism of the G6PD deficiency against 
malaria remains hypothetical and various mechanisms are 
developed[20]. This study shows that the variant 202A/376G G6PD 
A- is associated with the protection against asymptomatic 
malaria in Burkina Faso. However, other genotyping studies are 
needed to confirm the absence of other deficient variants, and 
to determine more accurately the 202A/376G mutation frequency 
in the general population and specific ethnic groups.
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Background
   The G6PD deficiency is the most common disease-
producing enzymopathy in humans. Its prevalence is highest 
in malaria endemic areas, because of the selective advantage 
conferred to carriers against malaria. Approximately 140 
mutations or combinations of mutations responsible for this 
deficiency have been described.
Research frontiers
   In this study, four combinations of mutations responsible 
for the G6PD deficiency were investigated in a rural 
community in Burkina Faso. This study showed that the 
202A/376G G6PD A- variant associated with protection 
against a symptomatic malaria in Burkina Faso is probably 
the most common deficient variant.
Related reports
   Approximately, 140 mutations or combinations of mutations 
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responsible for this deficiency have been described. The 
G6PD deficiency has been explored by the enzymatic 
activities in Burkina Faso. The genotyping of the G6PD 
variants have been reported on single 202A/376G G6PD A- 
variant in Africa, and also on 376G/542T, 376G/968C and 
T968C in the Gambia.
Innovations and breakthroughs
   Four deficient genotypes (202A/376G, 376G/542T, 376G/680T 
and 376G/968T), responsible for G6PD deficiency were 
searched in Burkina Faso, but only the genotype 202A/376G 
G6PD A- was found. Results showed that there was an 
association between the G6PD deficiency and the protection 
against asymptomatic malaria.
 
Applications
   The authors investigated mutations which are responsible 
for G6PD deficiency in individuals living in a malaria 
endemic area. It may be significant to know the genotyping 
of the G6PD variants. Accumulation of the additional 
information may lead to the solution of the protection 
mechanism of the G6PD deficiency against malaria.
Peer review
   This is a good study in which the authors showed that 
the G6PD A- variant associated with protection against a 
symptomatic malaria in Burkina Faso was probably the most 
common deficient variant. The results suggested that G6PD 
deficiency seemed to prevent the normal development of P. 
falciparum in the body.
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